WO2026132867 - HOCI-PFP-ALGINATE-CHITOSAN NANOPARTICLES PRODUCTION METHOD AS A LUNG CANCER ANTIBODY
National phase entry is expected:
Publication Number
WO/2026/132867
Publication Date
25.06.2026
International Application No.
PCT/IB2024/062818
International Filing Date
18.12.2024
Title **
[English]
HOCI-PFP-ALGINATE-CHITOSAN NANOPARTICLES PRODUCTION METHOD AS A LUNG CANCER ANTIBODY
[French]
PROCÉDÉ DE PRODUCTION DE NANOPARTICULES D'HOCI-PFP-ALGINATE-CHITOSANE EN TANT QU'ANTICORPS CONTRE LE CANCER DU POUMON
Applicants **
AGHAZADEH, Hamed
KAYA, Ali
SHAMLOUEI, Mostafa
ABOULHASSANZADEH, Sobhan
ABOULHASSANZADEH, Samin
HOMAYOON, Shidoosh
ZAREI, Alireza
KARIMI, Parvin
PARSA, Mahsa
GHADERMARZI, Parastoo
SADEGHI, Fatemeh
SALMANIOMOUMI, Reza
Inventors
AGHAZADEH, Hamed
KAYA, Ali
SHAMLOUEI, Mostafa
ABOULHASSANZADEH, Sobhan
ABOULHASSANZADEH, Samin
HOMAYOON, Shidoosh
ZAREI, Alireza
KARIMI, Parvin
PARSA, Mahsa
GHADERMARZI, Parastoo
SADEGHI, Fatemeh
SALMANIOMOUMI, Reza
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2888 | |
| EPO | Filing, Examination, Granting | 19259 | |
| Japan | Filing, Examination, Granting | 3140 | |
| South Korea | Filing, Examination, Granting | 4124 | |
| USA | Filing, Examination, Granting | 34140 |
Total:
63,551
Contact Us
Abstract[English]
to release HOC1, and the outer layer has a chitosan coating with folate and salicylic acid for targeting and proton release. The production process involves nanoemulsion and coating with the ionic gelation technique. When the nanoparticles are delivered to the lungs and targeted to cancer cells with folate, ultrasound radiation triggers the release of HOC1 to induce apoptosis and destroy cancer cells effectively, reducing side effects and improving treatment outcomes for lung cancer patients.[French]
pour libérer l'HOCl, et la couche externe présente un revêtement de chitosane avec du folate et de l'acide salicylique pour le ciblage et la libération de protons. Le procédé de production implique une nanoémulsion et un revêtement mettant en œuvre la technique de gélification ionique. Lorsque les nanoparticules sont administrées aux poumons et ciblées vers les cellules cancéreuses avec le folate, un rayonnement ultrasonore déclenche la libération d'HOCl pour induire l'apoptose et détruire efficacement les cellules cancéreuses, ce qui permet de réduire les effets secondaires et d'améliorer les résultats du traitement pour les patients atteints d'un cancer du poumon.